Skip to main content



Status: One Wales interim decision

Using the agreed starting and stopping criteria adalimumab can continue to be made available within NHS Wales to treat paediatric patients (aged ≥ 2 to ≤ 18 years) with severe refractory non-infectious intermediate, posterior and pan- uveitis. Adalimumab should be initiated in specialist centres for this indication.

Adalimumab is not licensed to treat this indication and is therefore ‘off-label’. Each provider organisation must ensure all internal governance arrangements are completed before this medicine is prescribed.

The risks and benefits of the off-label use of adalimumab for this indication should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

In August 2016 OWMAG recommended this treatment in NHS Wales, in November 2023 there was a review of the recommendation. OWMAG found nothing new that effects the original decision.

Next review: this decision will be reviewed again after three years or earlier if new evidence becomes available.

 One Wales Interim Decision (with start stop criteria and evidence review): Adalimumab for paediatric uveitis (OW04 2023 review) (PDF, 117Kb)

Medicine details

Medicine name adalimumab
Formulation Solution for injection (pre-filled pen, pre-filled syringe or vial)
Reference number OW04

For the treatment of paediatric patients with severe refractory non-infectious intermediate, posterior and pan-uveitis.

Company Various
BNF chapter Eye
Submission type One Wales
Status One Wales interim decision
Date of issue 21/10/2016
Date of last review November 2023
Follow AWTTC: